The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib
Sign Up to like & getrecommendations! Published in 2020 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-020-00596-z
Abstract: Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with… read more here.
Keywords: pacritinib; jak; generation jak; myeloproliferative neoplasms ... See more keywords